{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:38:40Z","timestamp":1783996720357,"version":"3.55.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/jac\/dky235","type":"journal-article","created":{"date-parts":[[2018,5,27]],"date-time":"2018-05-27T15:06:13Z","timestamp":1527433573000},"page":"2748-2756","source":"Crossref","is-referenced-by-count":64,"title":["Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316"],"prefix":"10.1093","volume":"73","author":[{"given":"Michael A","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"},{"name":"University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R","family":"Duncan","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"key\n\t\t\t\t20180921035222_dky235-B1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"key\n\t\t\t\t20180921035222_dky235-B2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic","volume":"23","author":"David","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180921035222_dky235-B3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180921035222_dky235-B4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.tim.2017.01.004","article-title":"Multidrug-resistant enterococcal infections: new compounds, novel antimicrobial therapies?","volume":"25","author":"van Harten","year":"2017","journal-title":"Trends Microbiol"},{"key":"key\n\t\t\t\t20180921035222_dky235-B5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20180921035222_dky235-B6","author":"WHO","year":"2017"},{"key":"key\n\t\t\t\t20180921035222_dky235-B7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jgar.2017.05.019","article-title":"Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: an in-depth review of newer antibiotics active against an enduring pathogen","volume":"10","author":"Bal","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"key\n\t\t\t\t20180921035222_dky235-B8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/cid\/cir326","article-title":"Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States","volume":"53","author":"Rosen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180921035222_dky235-B9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","article-title":"New and improved? A review of novel antibiotics for Gram-positive bacteria","volume":"23","author":"Abbas","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180921035222_dky235-B10","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1128\/AAC.03344-14","article-title":"Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States","volume":"58","author":"Richter","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035222_dky235-B11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijantimicag.2017.05.006","article-title":"Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new","volume":"50","author":"David","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180921035222_dky235-B12","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035222_dky235-B13","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180921035222_dky235-B14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1001\/jama.2014.6364","article-title":"Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis","volume":"312","author":"Kalil","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180921035222_dky235-B15","doi-asserted-by":"crossref","first-page":"217.","DOI":"10.3389\/fpubh.2014.00217","article-title":"Vancomycin revisited\u201460 years later","volume":"2","author":"Rubinstein","year":"2014","journal-title":"Front Public Health"},{"key":"key\n\t\t\t\t20180921035222_dky235-B16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180921035222_dky235-B17","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Seventh Informational Supplement M100-S27","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"key\n\t\t\t\t20180921035222_dky235-B18","author":"EUCAST","year":"2017"},{"key":"key\n\t\t\t\t20180921035222_dky235-B19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180921035222_dky235-B20","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1128\/JCM.03395-15","article-title":"New Gram-positive agents: the next generation of oxazolidinones and lipoglycopeptides","volume":"54","author":"Crotty","year":"2016","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180921035222_dky235-B21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/phar.1641","article-title":"Dalbavancin and oritavancin: an innovative approach to the treatment of Gram-positive infections","volume":"35","author":"Roberts","year":"2015","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20180921035222_dky235-B22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180921035222_dky235-B23","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180921035222_dky235-B24"},{"key":"key\n\t\t\t\t20180921035222_dky235-B25","doi-asserted-by":"crossref","first-page":"1260.","DOI":"10.1128\/AAC.01453-08","article-title":"Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates","volume":"53","author":"Biedenbach","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035222_dky235-B26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ijantimicag.2016.04.009","article-title":"In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011\u20132013)","volume":"47","author":"Huband","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180921035222_dky235-B27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2010.10.031","article-title":"In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Karlowsky","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180921035222_dky235-B28","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/AAC.00274-15","article-title":"In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program","volume":"59","author":"McCurdy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180921035222_dky235-B29","first-page":"e02397","author":"Sader","year":"2018"},{"key":"key\n\t\t\t\t20180921035222_dky235-B30","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1517\/14656566.2015.1075508","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infections","volume":"16","author":"Ramdeen","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t20180921035222_dky235-B31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-015-0430-x","article-title":"Dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180921035222_dky235-B32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0732-8893(01)00318-2","article-title":"Determining the value of antimicrobial surveillance programs","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180921035222_dky235-B33","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Tenth Edition: Approved Standard M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"key\n\t\t\t\t20180921035222_dky235-B34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-016-0666-0","article-title":"Single-dose dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180921035222_dky235-B35","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180921035222_dky235-B36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jac\/dkv303","article-title":"Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011\u201313)","volume":"71","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180921035222_dky235-B37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jgar.2017.06.003","article-title":"Activity of dalbavancin tested against gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014\u20132015)","volume":"11","author":"Pfaller","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"key\n\t\t\t\t20180921035222_dky235-B38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect Dis Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/10\/2748\/25770283\/dky235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T13:01:02Z","timestamp":1571403662000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/10\/2748\/5046993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,6,29]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky235","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,6,29]]}}}